Meenhard Herlyn - Publications

Affiliations: 
Bioengineering University of Pennsylvania, Philadelphia, PA, United States 
Area:
Biomedical Engineering, Oncology, Cell Biology

275 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, Ecker BL, Yang R, Feltcher C, Peng K, Feng C, ... ... Herlyn M, et al. Author Correction: Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature Communications. 10: 1211. PMID 30858377 DOI: 10.1038/s41467-019-09195-w  1
2019 Sahu AD, S Lee J, Wang Z, Zhang G, Iglesias-Bartolome R, Tian T, Wei Z, Miao B, Nair NU, Ponomarova O, Friedman AA, Amzallag A, Moll T, Kasumova G, Greninger P, ... ... Herlyn M, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Molecular Systems Biology. 15: e8323. PMID 30858180 DOI: 10.15252/msb.20188323  1
2019 Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards AD, Moberg VE, Pilon-Thomas S, Schell MJ, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, et al. BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30765391 DOI: 10.1158/1078-0432.CCR-18-2725  1
2018 Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, Ecker B, Yang R, Feltcher C, Peng K, Feng C, ... ... Herlyn M, et al. Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature Communications. 9: 5426. PMID 30575721 DOI: 10.1038/s41467-018-07126-9  1
2018 Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Liu S, Xu X, Krepler C, Xiao M, ... ... Herlyn M, et al. ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discovery. PMID 30563872 DOI: 10.1158/2159-8290.CD-18-0348  1
2018 Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, ... ... Herlyn M, et al. Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. PMID 30532003 DOI: 10.1038/s41586-018-0814-7  1
2018 Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A, McAfee Q, McLaughlin NP, Zhang G, Goldman AR, Ojha R, Piao S, Noguera-Ortega E, Martorella A, Alicea GM, ... ... Herlyn M, et al. PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discovery. PMID 30442709 DOI: 10.1158/2159-8290.CD-18-0706  1
2018 Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, ... ... Herlyn M, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 175: 984-997.e24. PMID 30388455 DOI: 10.1016/j.cell.2018.09.006  1
2018 Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine. PMID 30333558 DOI: 10.1038/s41591-018-0247-8  1
2018 Pathria G, Scott DA, Feng Y, Sang Lee J, Fujita Y, Zhang G, Sahu AD, Ruppin E, Herlyn M, Osterman AL, Ronai ZA. Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. The Embo Journal. PMID 30209241 DOI: 10.15252/embj.201899735  1
2018 Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine. PMID 30127394 DOI: 10.1038/s41591-018-0157-9  1
2018 Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, ... ... Herlyn M, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nature Medicine. PMID 30038220 DOI: 10.1038/s41591-018-0116-5  1
2018 Zhou Y, Chen X, Kang B, She S, Zhang X, Chen C, Li W, Chen W, Dan S, Pan X, Liu X, He J, Zhao Q, Zhu C, Peng L, ... ... Herlyn M, et al. Endogenous authentic OCT4A proteins directly regulate FOS/AP-1 transcription in somatic cancer cells. Cell Death & Disease. 9: 585. PMID 29789579 DOI: 10.1038/s41419-018-0606-x  0.92
2018 Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, ... ... Herlyn M, et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. Embo Molecular Medicine. PMID 29650805 DOI: 10.15252/emmm.201708446  1
2018 Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, ... ... Herlyn M, et al. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29563139 DOI: 10.1158/1078-0432.CCR-17-2773  1
2018 Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, ... ... Herlyn M, et al. Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget. 9: 8206-8222. PMID 29492189 DOI: 10.18632/oncotarget.23654  1
2018 Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, Eggan E, Anastopoulos IN, Vargas-Garcia CA, Singh A, Nathanson KL, ... Herlyn M, et al. Corrigendum: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. PMID 29466340 DOI: 10.1038/nature25162  0.36
2017 Liu S, Tetzlaff MT, Wang T, Chen X, Yang R, Kumar SM, Vultur A, Li P, Martin JS, Herlyn M, Amaravadi R, Li B, Xu X. Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma. Oncotarget. 8: 115140-115152. PMID 29383148 DOI: 10.18632/oncotarget.22944  0.36
2017 Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H. Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS- Mutant Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29196297 DOI: 10.1158/1078-0432.CCR-16-2118  0.36
2017 Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, ... ... Herlyn M, et al. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports. 21: 1953-1967. PMID 29141225 DOI: 10.1016/j.celrep.2017.10.021  1
2017 Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, ... ... Herlyn M, et al. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports. 21: 1936-1952. PMID 29141224 DOI: 10.1016/j.celrep.2017.10.052  0.36
2017 Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, ... ... Herlyn M, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery. PMID 29101162 DOI: 10.1158/2159-8290.CD-17-0833  1
2017 Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, ... ... Herlyn M, et al. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. PMID 28953887 DOI: 10.1038/nature24040  1
2017 Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, ... ... Herlyn M, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications. 8: 607. PMID 28928360 DOI: 10.1038/s41467-017-00452-4  1
2017 Rebecca VW, Nicastri MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, Nofal M, Lim CY, Witze E, Chude CI, Zhang G, Alicea GM, Piao S, Murugan S, Ojha R, ... ... Herlyn M, et al. A unified approach to targeting the lysosome's degradative and growth signaling roles. Cancer Discovery. PMID 28899863 DOI: 10.1158/2159-8290.CD-17-0741  1
2017 Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, ... ... Herlyn M, et al. Enhancing CD8(+) T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 32: 377-391.e9. PMID 28898698 DOI: 10.1016/j.ccell.2017.08.004  1
2017 Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, Eggan E, Anastopoulos IN, Vargas-Garcia CA, Singh A, Nathanson KL, ... Herlyn M, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. PMID 28607484 DOI: 10.1038/nature22794  0.36
2017 Leu JI, Barnoud T, Zhang G, Tian T, Wei Z, Herlyn M, Murphy ME, George DL. Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function. Oncotarget. PMID 28484090 DOI: 10.18632/oncotarget.17321  1
2017 Zhang D, Zhang G, Hu X, Wu L, Feng Y, He S, Zhang Y, Hu Z, Yang L, Tian T, Xu W, Wei Z, Lu Y, Flaherty KT, Zhong X, ... ... Herlyn M, et al. Oncogenic RAS regulates long non-coding RNA Orilnc1 in human cancer. Cancer Research. PMID 28473531 DOI: 10.1158/0008-5472.CAN-16-1768  1
2017 Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, ... ... Herlyn M, et al. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 8: 25395-25417. PMID 28445987 DOI: 10.18632/oncotarget.15915  1
2016 Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MC, Yoshida A, Qie S, Zhang G, Chajewski OS, Wu L, Majsterek I, Herlyn M, Fuchs SY, Diehl JA. PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. Plos Genetics. 12: e1006518. PMID 27977682 DOI: 10.1371/journal.pgen.1006518  1
2016 Krepler C, Xiao M, Samanta M, Vultur A, Chen HY, Brafford P, Reyes-Uribe PI, Halloran M, Chen T, He X, Hristova D, Liu Q, Samatar AA, Davies MA, Nathanson KL, ... ... Herlyn M, et al. Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget. PMID 27655717 DOI: 10.18632/oncotarget.12078  0.36
2016 Wu LW, Zhang G, Herlyn M. Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma. Molecular & Cellular Oncology. 3: e1179381. PMID 27652325 DOI: 10.1080/23723556.2016.1179381  1
2016 Shannan B, Watters A, Chen Q, Mollin S, Dörr M, Meggers E, Xu X, Gimotty PA, Perego M, Li L, Benci J, Krepler C, Brafford P, Zhang J, Wei Z, ... ... Herlyn M, et al. PIM kinases as therapeutic targets against advanced melanoma. Oncotarget. PMID 27448973 DOI: 10.18632/oncotarget.10703  1
2016 Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, ... ... Herlyn M, et al. Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Reports. PMID 27210749 DOI: 10.1016/j.celrep.2016.04.073  1
2016 Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, ... ... Herlyn M, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. The Journal of Clinical Investigation. PMID 27043285 DOI: 10.1172/JCI82661  1
2016 Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, ... Herlyn M, et al. Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell & Melanoma Research. PMID 26850518 DOI: 10.1111/pcmr.12465  0.36
2016 Shannan B, Perego M, Somasundaram R, Herlyn M. Heterogeneity in Melanoma. Cancer Treatment and Research. 167: 1-15. PMID 26601857 DOI: 10.1007/978-3-319-22539-5_1  1
2015 Krepler C, Xiao M, Spoesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, ... ... Herlyn M, et al. Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26673799 DOI: 10.1158/1078-0432.CCR-15-1762  0.36
2015 Wang YJ, Herlyn M. The emerging roles of Oct4 in tumor-initiating cells. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. American Journal of Physiology. Cell Physiology. ajpcell.00212.2015. PMID 26447206 DOI: 10.1152/ajpcell.00212.2015  0.92
2015 Somasundaram R, Herlyn M. Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Review of Anticancer Therapy. 15: 1135-41. PMID 26402246 DOI: 10.1586/14737140.2015.1093418  0.92
2015 Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, et al. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports. 11: 1458-73. PMID 26027934 DOI: 10.1016/j.celrep.2015.04.049  0.92
2015 Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, ... Herlyn M, et al. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell & Melanoma Research. 28: 431-41. PMID 25903073 DOI: 10.1111/pcmr.12379  1
2015 Joshi S, Wels C, Beham-Schmid C, Fukunaga-Kalabis M, Holmen SL, Otte M, Herlyn M, Waldhoer M, Schaider H. Gα13 mediates human cytomegalovirus-encoded chemokine receptor US28-induced cell death in melanoma. International Journal of Cancer. Journal International Du Cancer. 137: 1503-8. PMID 25754407 DOI: 10.1002/ijc.29506  1
2015 Fukunaga-Kalabis M, Hristova DM, Wang JX, Li L, Heppt MV, Wei Z, Gyurdieva A, Webster MR, Oka M, Weeraratna AT, Herlyn M. UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch. The Journal of Investigative Dermatology. 135: 1521-32. PMID 25705850 DOI: 10.1038/jid.2015.59  1
2015 Arner E, Daub CO, Vitting-Seerup K, Andersson R, Lilje B, Drabløs F, Lennartsson A, Rönnerblad M, Hrydziuszko O, Vitezic M, Freeman TC, Alhendi AM, Arner P, Axton R, Baillie JK, ... ... Herlyn M, et al. Gene regulation. Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (New York, N.Y.). 347: 1010-4. PMID 25678556 DOI: 10.1126/science.1259418  1
2015 Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, ... Herlyn M, et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. PMID 25619837 DOI: 10.1038/onc.2014.432  1
2015 Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, ... ... Herlyn M, et al. BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1652-64. PMID 25617424 DOI: 10.1158/1078-0432.CCR-14-1554  1
2015 Slipicevic A, Herlyn M. KIT in melanoma: many shades of gray. The Journal of Investigative Dermatology. 135: 337-8. PMID 25573046 DOI: 10.1038/jid.2014.417  1
2015 Kraya AA, Piao S, Xu X, Zhang G, Herlyn M, Gimotty P, Levine B, Amaravadi RK, Speicher DW. Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy. 11: 60-74. PMID 25484078 DOI: 10.4161/15548627.2014.984273  1
2015 Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, ... ... Herlyn M, et al. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell & Melanoma Research. 28: 184-95. PMID 25407936 DOI: 10.1111/pcmr.12330  1
2014 Yang R, Zheng Y, Li L, Liu S, Burrows M, Wei Z, Nace A, Herlyn M, Cui R, Guo W, Cotsarelis G, Xu X. Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors. Nature Communications. 5: 5807. PMID 25510211 DOI: 10.1038/ncomms6807  1
2014 Ravindran Menon D, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Bonyadi Rad E, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, ... Herlyn M, et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. PMID 25417704 DOI: 10.1038/onc.2014.372  1
2014 Zhang G, Herlyn M. Linking SOX10 to a slow-growth resistance phenotype. Cell Research. 24: 906-7. PMID 24853952 DOI: 10.1038/cr.2014.67  1
2014 Somasundaram R, Herlyn M. Indomethacin to the rescue of TRAIL-resistant melanomas. The Journal of Investigative Dermatology. 134: 1198-9. PMID 24732334 DOI: 10.1038/jid.2014.1  1
2014 Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, et al. LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. Cancer Research. 74: 1390-403. PMID 24590809 DOI: 10.1158/0008-5472.CAN-13-1275  1
2014 Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, ... ... Herlyn M, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. The Journal of Clinical Investigation. 124: 1406-17. PMID 24569374 DOI: 10.1172/JCI70454  1
2014 Geserick P, Herlyn M, Leverkus M. On the TRAIL to overcome BRAF-inhibitor resistance. The Journal of Investigative Dermatology. 134: 315-8. PMID 24424456 DOI: 10.1038/jid.2013.348  1
2014 Slipicevic A, Somasundaram R, Sproesser K, Herlyn M. Isolation of melanoma cell subpopulations using negative selection. Methods in Molecular Biology (Clifton, N.J.). 1102: 501-12. PMID 24258995 DOI: 10.1007/978-1-62703-727-3_26  1
2014 Wang T, Ge Y, Xiao M, Lopez-Coral A, Li L, Roesch A, Huang C, Alexander P, Vogt T, Xu X, Hwang WT, Lieu M, Belser E, Liu R, Somasundaram R, ... Herlyn M, et al. SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. The Journal of Investigative Dermatology. 134: 1108-18. PMID 24157461 DOI: 10.1038/jid.2013.437  1
2014 Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, Sudol M, Herlyn M, Mauviel A. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. The Journal of Investigative Dermatology. 134: 123-32. PMID 23897276 DOI: 10.1038/jid.2013.319  1
2014 Somasundaram R, Facompre N, Herlyn M. Melanoma Subpopulations with Cancer Stem Cell Phenotypes Cancer Stem Cells. 223-234. DOI: 10.1002/9781118356203.ch17  1
2013 O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discovery. 3: 1378-93. PMID 24104062 DOI: 10.1158/2159-8290.CD-13-0005  1
2013 Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, ... ... Herlyn M, et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Reports. 4: 1090-9. PMID 24055054 DOI: 10.1016/j.celrep.2013.08.023  1
2013 Rasanen K, Sriswasdi S, Valiga A, Tang HY, Zhang G, Perego M, Somasundaram R, Li L, Speicher K, Klein-Szanto AJ, Basu D, Rustgi AK, Speicher DW, Herlyn M. Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. Molecular & Cellular Proteomics : McP. 12: 3778-92. PMID 24037664 DOI: 10.1074/mcp.M113.029587  1
2013 Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl JN, Pytel D, Barbash O, Schuchter L, Amaravaradi R, Xu X, Herlyn M, Nathanson KL, Diehl JA. The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Molecular and Cellular Biology. 33: 4422-33. PMID 24019069 DOI: 10.1128/MCB.00706-13  1
2013 Basu D, Bewley AF, Sperry SM, Montone KT, Gimotty PA, Rasanen K, Facompre ND, Weinstein GS, Nakagawa H, Diehl JA, Rustgi AK, Herlyn M. EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. Molecular Cancer Therapeutics. 12: 2176-86. PMID 23939378 DOI: 10.1158/1535-7163.MCT-12-1210  1
2013 Kwak J, Gallagher M, Ozdener MH, Wysocki CJ, Goldsmith BR, Isamah A, Faranda A, Fakharzadeh SS, Herlyn M, Johnson AT, Preti G. Volatile biomarkers from human melanoma cells. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 931: 90-6. PMID 23770738 DOI: 10.1016/j.jchromb.2013.05.007  1
2013 Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Pätzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, ... ... Herlyn M, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 23: 811-25. PMID 23764003 DOI: 10.1016/j.ccr.2013.05.003  1
2013 Wang T, Herlyn M. The macrophage: a new factor in UVR-induced melanomagenesis. The Journal of Investigative Dermatology. 133: 1711-3. PMID 23760048 DOI: 10.1038/jid.2013.93  1
2013 Vultur A, Herlyn M. SnapShot: melanoma. Cancer Cell. 23: 706-706.e1. PMID 23680152 DOI: 10.1016/j.ccr.2013.05.001  1
2013 Kastl A, Dieckmann S, Wähler K, Völker T, Kastl L, Merkel AL, Vultur A, Shannan B, Harms K, Ocker M, Parak WJ, Herlyn M, Meggers E. Rhenium complexes with visible-light-induced anticancer activity. Chemmedchem. 8: 924-7. PMID 23568508 DOI: 10.1002/cmdc.201300060  1
2013 Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Reports. 3: 1252-65. PMID 23562156 DOI: 10.1016/j.celrep.2013.03.004  1
2013 Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M. Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell & Melanoma Research. 26: E8-E14. PMID 23531109 DOI: 10.1111/pcmr.12099  1
2013 Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, Smalley KS, Herlyn M. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. Plos One. 8: e59588. PMID 23527225 DOI: 10.1371/journal.pone.0059588  1
2013 Swoboda RK, Herlyn M. There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis. Experimental Dermatology. 22: 303-6. PMID 23489578 DOI: 10.1111/exd.12117  1
2013 Li L, Fukunaga-Kalabis M, Herlyn M. Isolation, characterization, and differentiation of human multipotent dermal stem cells. Methods in Molecular Biology (Clifton, N.J.). 989: 235-46. PMID 23483399 DOI: 10.1007/978-1-62703-330-5_18  1
2013 Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, McKinlay M, Herlyn M. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1784-94. PMID 23403634 DOI: 10.1158/1078-0432.CCR-12-2518  1
2013 Wang T, Somasundaram R, Herlyn M. Combination therapy of immunocytokines with ipilimumab: a cure for melanoma? The Journal of Investigative Dermatology. 133: 595-6. PMID 23399823 DOI: 10.1038/jid.2012.433  1
2013 Somasundaram R, Herlyn M. Relapse of melanoma after successful adoptive T-cell therapy: escape through inflammation-induced phenotypic melanoma cell plasticity. Pigment Cell & Melanoma Research. 26: 2-4. PMID 23387000 DOI: 10.1111/pcmr.12038  1
2013 Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva J, Dunbrack RL, Yen T, George DL, Murphy ME. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Molecular Cancer Research : McR. 11: 219-29. PMID 23303345 DOI: 10.1158/1541-7786.MCR-12-0547-T  1
2012 Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M, Krepler C, Vultur A, Xu W, Yu GH, Schuchter L, Clark DP. Functional profiling of live melanoma samples using a novel automated platform. Plos One. 7: e52760. PMID 23285177 DOI: 10.1371/journal.pone.0052760  1
2012 Fukunaga-Kalabis M, Herlyn M. Cancer: Complexion matters. Nature. 491: 342-3. PMID 23123853 DOI: 10.1038/nature11641  1
2012 Fukunaga-Kalabis M, Herlyn M. Beyond ABC: another mechanism of drug resistance in melanoma side population. The Journal of Investigative Dermatology. 132: 2317-9. PMID 22971921 DOI: 10.1038/jid.2012.220  1
2012 Räsänen K, Herlyn M. Paracrine signaling between carcinoma cells and mesenchymal stem cells generates cancer stem cell niche via epithelial-mesenchymal transition. Cancer Discovery. 2: 775-7. PMID 22969117 DOI: 10.1158/2159-8290.CD-12-0312  1
2012 Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Advances in Pharmacology (San Diego, Calif.). 65: 335-59. PMID 22959031 DOI: 10.1016/B978-0-12-397927-8.00011-7  1
2012 Facompre N, Nakagawa H, Herlyn M, Basu D. Stem-like cells and therapy resistance in squamous cell carcinomas. Advances in Pharmacology (San Diego, Calif.). 65: 235-65. PMID 22959028 DOI: 10.1016/B978-0-12-397927-8.00008-7  1
2012 Tchou J, Kossenkov AV, Chang L, Satija C, Herlyn M, Showe LC, Puré E. Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles. Bmc Medical Genomics. 5: 39. PMID 22954256 DOI: 10.1186/1755-8794-5-39  1
2012 Zhang G, Herlyn M. Human nevi: no longer precursors of melanomas? The Journal of Investigative Dermatology. 132: 2133-4. PMID 22895446 DOI: 10.1038/jid.2012.183  1
2012 Kong X, Qin J, Li Z, Vultur A, Tong L, Feng E, Rajan G, Liu S, Lu J, Liang Z, Zheng M, Zhu W, Jiang H, Herlyn M, Liu H, et al. Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Organic & Biomolecular Chemistry. 10: 7402-17. PMID 22875039 DOI: 10.1039/c2ob26081f  1
2012 John JK, Paraiso KH, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KS. GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. The Journal of Investigative Dermatology. 132: 2818-27. PMID 22810307 DOI: 10.1038/jid.2012.237  1
2012 Somasundaram R, Herlyn M. Melanoma exosomes: messengers of metastasis. Nature Medicine. 18: 853-4. PMID 22673991 DOI: 10.1038/nm.2775  1
2012 Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, et al. Genomic characterisation of acral melanoma cell lines. Pigment Cell & Melanoma Research. 25: 488-92. PMID 22578220 DOI: 10.1111/j.1755-148X.2012.01016.x  1
2012 Qin J, Xie P, Ventocilla C, Zhou G, Vultur A, Chen Q, Liu Q, Herlyn M, Winkler J, Marmorstein R. Identification of a novel family of BRAF(V600E) inhibitors. Journal of Medicinal Chemistry. 55: 5220-30. PMID 22537109 DOI: 10.1021/jm3004416  1
2012 Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, Zhang G, Wei Z, Xu X, Rauscher FJ, Herlyn M, Kaufman RE. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell & Melanoma Research. 25: 493-505. PMID 22498258 DOI: 10.1111/j.1755-148X.2012.01005.x  1
2012 Herlyn M. New dream team for melanoma therapy. Pigment Cell & Melanoma Research. 25: 279-80. PMID 22462086 DOI: 10.1111/j.1755-148X.2012.00968.x  1
2012 Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W, Brunner P, Grabmeier-Pfistershammer K, Gschaider M, Lai CY, Hsu MY, Herlyn M, Stingl G, Wagner SN. Targeting CD20 in melanoma patients at high risk of disease recurrence. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1056-62. PMID 22354376 DOI: 10.1038/mt.2012.27  1
2012 Slipicevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Upsala Journal of Medical Sciences. 117: 237-43. PMID 22339359 DOI: 10.3109/03009734.2012.658977  1
2012 Lee JT, Herlyn M. MEK'ing the most of p53 reactivation therapy in melanoma. The Journal of Investigative Dermatology. 132: 263-5. PMID 22241441 DOI: 10.1038/jid.2011.362  1
2012 Kalabis J, Wong GS, Vega ME, Natsuizaka M, Robertson ES, Herlyn M, Nakagawa H, Rustgi AK. Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nature Protocols. 7: 235-46. PMID 22240585 DOI: 10.1038/nprot.2011.437  1
2012 Li L, Fukunaga-Kalabis M, Herlyn M. Isolation and cultivation of dermal stem cells that differentiate into functional epidermal melanocytes. Methods in Molecular Biology (Clifton, N.J.). 806: 15-29. PMID 22057442 DOI: 10.1007/978-1-61779-367-7_2  1
2012 Herlyn M. Randy Lomax - the passionate melanoma advocate and champion of the Melanoma Research Foundation Pigment Cell and Melanoma Research. DOI: 10.1111/j.1755-148X.2012.01030.x  1
2011 Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Research. 71: 7137-40. PMID 22131348 DOI: 10.1158/0008-5472.CAN-11-1243  1
2011 Zabierowski SE, Baubet V, Himes B, Li L, Fukunaga-Kalabis M, Patel S, McDaid R, Guerra M, Gimotty P, Dahmane N, Dahamne N, Herlyn M. Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor. Stem Cells (Dayton, Ohio). 29: 1752-62. PMID 21948558 DOI: 10.1002/stem.740  1
2011 Herlyn M, Villanueva J. Sorting through the many opportunities for melanoma therapy. Pigment Cell & Melanoma Research. 24: 975-7. PMID 21899726 DOI: 10.1111/j.1755-148X.2011.00906.x  1
2011 Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, Kalman RA, Nakagawa M, Darling DS, Basu D, Gimotty PA, Klein-Szanto AJ, Diehl JA, Herlyn M, Nakagawa H. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Research. 71: 6836-47. PMID 21890822 DOI: 10.1158/0008-5472.CAN-11-0846  1
2011 Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. Journal of Visualized Experiments : Jove. PMID 21847077 DOI: 10.3791/2937  1
2011 Fukunaga-Kalabis M, Roesch A, Herlyn M. From cancer stem cells to tumor maintenance in melanoma. The Journal of Investigative Dermatology. 131: 1600-4. PMID 21654838 DOI: 10.1038/jid.2011.159  1
2011 Basu D, Montone KT, Wang LP, Gimotty PA, Hammond R, Diehl JA, Rustgi AK, Lee JT, Rasanen K, Weinstein GS, Herlyn M. Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (Georgetown, Tex.). 10: 2008-16. PMID 21558812 DOI: 10.4161/cc.10.12.15883  1
2011 Somasundaram R, Villanueva J, Herlyn M. Will engineered T cells expressing CD20 scFv eradicate Melanoma? Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 638-40. PMID 21455210 DOI: 10.1038/mt.2011.46  1
2011 Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1658-63. PMID 21447722 DOI: 10.1158/1078-0432.CCR-10-0174  1
2010 Bogenrieder T, Herlyn M. The molecular pathology of cutaneous melanoma. Cancer Biomarkers : Section a of Disease Markers. 9: 267-86. PMID 22112480 DOI: 10.3233/CBM-2011-0164  1
2010 Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, ... ... Herlyn M, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18: 683-95. PMID 21156289 DOI: 10.1016/j.ccr.2010.11.023  1
2010 Han MJ, Wang H, Beer LA, Tang HY, Herlyn M, Speicher DW. A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling. Proteomics. 10: 4450-62. PMID 21136598 DOI: 10.1002/pmic.200900549  1
2010 Herlyn M, Nathanson KL. Taking the guesswork out of uveal melanoma. The New England Journal of Medicine. 363: 2256-7. PMID 21083377 DOI: 10.1056/NEJMe1010681  1
2010 Herlyn M. Boris Bastian. Pigment Cell & Melanoma Research. 23: 834. PMID 20973934 DOI: 10.1111/j.1755-148X.2010.00724.x  1
2010 Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell & Melanoma Research. 23: 820-7. PMID 20973932 DOI: 10.1111/j.1755-148X.2010.00763.x  1
2010 Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, Nakagawa H, Herlyn M, Hua X, Rustgi AK, McMahon SB, Diehl JA. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell. 18: 329-40. PMID 20951943 DOI: 10.1016/j.ccr.2010.08.012  1
2010 Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, Kalman RA, Nakagawa M, Wu L, Klein-Szanto AJ, Herlyn M, Diehl JA, Katz JP, Pear WS, Seykora JT, Nakagawa H. NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology. 139: 2113-23. PMID 20801121 DOI: 10.1053/j.gastro.2010.08.040  1
2010 Santiago-Walker A, Herlyn M. The ups and downs of transcription factors in melanoma. Journal of the National Cancer Institute. 102: 1103-4. PMID 20660367 DOI: 10.1093/jnci/djq267  1
2010 Michaylira CZ, Wong GS, Miller CG, Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ, Lee JS, Kim SB, Herlyn M, Diehl JA, Gimotty P, Rustgi AK. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Research. 70: 5281-92. PMID 20516120 DOI: 10.1158/0008-5472.CAN-10-0704  1
2010 Natsuizaka M, Ohashi S, Wong GS, Ahmadi A, Kalman RA, Budo D, Klein-Szanto AJ, Herlyn M, Diehl JA, Nakagawa H. Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis. 31: 1344-53. PMID 20513670 DOI: 10.1093/carcin/bgq108  1
2010 Basu D, Nguyen TT, Montone KT, Zhang G, Wang LP, Diehl JA, Rustgi AK, Lee JT, Weinstein GS, Herlyn M. Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene. 29: 4170-82. PMID 20498638 DOI: 10.1038/onc.2010.170  1
2010 Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 141: 583-94. PMID 20478252 DOI: 10.1016/j.cell.2010.04.020  1
2010 Ohashi S, Natsuizaka M, Wong GS, Michaylira CZ, Grugan KD, Stairs DB, Kalabis J, Vega ME, Kalman RA, Nakagawa M, Klein-Szanto AJ, Herlyn M, Diehl JA, Rustgi AK, Nakagawa H. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Research. 70: 4174-84. PMID 20424117 DOI: 10.1158/0008-5472.CAN-09-4614  1
2010 Herlyn M, Fukunaga-Kalabis M. What is a good model for melanoma? The Journal of Investigative Dermatology. 130: 911-2. PMID 20231823 DOI: 10.1038/jid.2009.441  1
2010 Zabierowski SE, Herlyn M. Embryonic stem cells as a model for studying melanocyte development. Methods in Molecular Biology (Clifton, N.J.). 584: 301-16. PMID 19907984 DOI: 10.1007/978-1-60761-369-5_16  1
2010 Degenhardt Y, Huang J, Greshock J, Horiates G, Nathanson K, Yang X, Herlyn M, Weber B. Distinct MHC gene expression patterns during progression of melanoma. Genes, Chromosomes & Cancer. 49: 144-54. PMID 19862823 DOI: 10.1002/gcc.20728  1
2009 Katz AB, Keswani SG, Habli M, Lim FY, Zoltick PW, Midrio P, Kozin ED, Herlyn M, Crombleholme TM. Placental gene transfer: transgene screening in mice for trophic effects on the placenta. American Journal of Obstetrics and Gynecology. 201: 499.e1-8. PMID 19716119 DOI: 10.1016/j.ajog.2009.06.029  1
2009 Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT, ... ... Herlyn M, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Research. 69: 5312-20. PMID 19549918 DOI: 10.1158/0008-5472.CAN-08-3767  1
2009 Herlyn M. Driving in the melanoma landscape. Experimental Dermatology. 18: 506-8. PMID 19366372 DOI: 10.1111/j.1600-0625.2009.00872.x  1
2009 Basu D, Herlyn M. Defining microenvironments within mouse models that enhance tumor aggressiveness. Cancer Biology & Therapy. 8: 380-1. PMID 19182538  1
2009 Passegué E, Rafii S, Herlyn M. Cancer stem cells are everywhere. Nature Medicine. 15: 23. PMID 19129778 DOI: 10.1038/nm0109-23  1
2009 Vultur A, Herlyn M. Cracking the system: Melanoma complexity demands new therapeutic approaches Pigment Cell and Melanoma Research. 22: 4-5. PMID 19054340 DOI: 10.1111/j.1755-148X.2008.00527.x  1
2009 Roesch A, Herlyn M. Melanoma cancer stem cells Cancer Stem Cells. 31-48. DOI: 10.1017/CBO9780511605536.004  1
2009 Smalley KSM, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy International Journal of Cancer. 124: 1245-1250. DOI: 10.1002/ijc.24129  1
2008 Fukunaga-Kalabis M, Santiago-Walker A, Herlyn M. Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. 1: 93-102. PMID 19308688 DOI: 10.1007/s12307-008-0009-0  1
2008 Zabierowski SE, Herlyn M. Melanoma stem cells: The dark seed of melanoma Journal of Clinical Oncology. 26: 2890-2894. PMID 18539969 DOI: 10.1200/JCO.2007.15.5465  1
2008 Lee JT, Brafford P, Herlyn M. Unraveling the mysteries of IGF-1 signaling in melanoma Journal of Investigative Dermatology. 128: 1358-1360. PMID 18478012 DOI: 10.1038/jid.2008.124  1
2008 Basu D, Herlyn M. Salmonella typhimurium as a novel RNA interference vector for cancer gene therapy. Cancer Biology & Therapy. 7: 151-2. PMID 18347415  1
2008 Zabierowski SE, Herlyn M. Learning the ABCs of Melanoma-Initiating Cells Cancer Cell. 13: 185-187. PMID 18328422 DOI: 10.1016/j.ccr.2008.02.015  1
2008 Villanueva J, Herlyn M. Melanoma and the tumor microenvironment Current Oncology Reports. 10: 439-446. DOI: 10.1007/s11912-008-0067-y  1
2007 Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 20: 458-65. PMID 17935489 DOI: 10.1111/j.1600-0749.2007.00410.x  1
2007 Fukunaga-Kalabis M, Herlyn M. Unraveling mysteries of the multifunctional protein SPARC Journal of Investigative Dermatology. 127: 2497-2498. PMID 17934501 DOI: 10.1038/sj.jid.5701050  1
2007 Lee JT, Herlyn M. Old disease, new culprit: Tumor stem cells in cancer Journal of Cellular Physiology. 213: 603-609. PMID 17786956 DOI: 10.1002/jcp.21252  1
2007 Lee JT, Herlyn M. Microenvironmental influences in melanoma progression Journal of Cellular Biochemistry. 101: 862-872. PMID 17171636 DOI: 10.1002/jcb.21204  1
2007 Herlyn M. Profiles and legacies: Farming cells to rebuild skin and melanoma Cancer Biology and Therapy. 6: 467-471. DOI: 10.4161/cbt.6.3.4118  1
2007 Gaddipati H, Herlyn M. Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma Cancer Journal. 13: 226-228. DOI: 10.1097/PPO.0b013e31813fffdd  1
2007 Fang D, Herlyn M. The Transformed Phenotype of Melanocytes The Pigmentary System: Physiology and Pathophysiology: Second Edition. 489-494. DOI: 10.1002/9780470987100.ch25  1
2006 Smalley KSM, Lioni M, Herlyn M. Life isn't flat: Taking cancer biology to the next dimension In Vitro Cellular and Developmental Biology - Animal. 42: 242-247. PMID 17163781  1
2006 Lee JT, Herlyn M. Embryogenesis meets tumorigenesis Nature Medicine. 12: 882-884. PMID 16892028 DOI: 10.1038/nm0806-882  1
2006 Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Research. 66: 4182-90. PMID 16618740 DOI: 10.1158/0008-5472.CAN-05-3589  1
2006 Smalley KSM, Herlyn M. Towards the targeted therapy of melanoma Mini-Reviews in Medicinal Chemistry. 6: 387-393. PMID 16613575 DOI: 10.2174/138955706776361402  1
2006 Liu ZJ, Xiao M, Balint K, Soma A, Pinnix CC, Capobianco AJ, Velazquez OC, Herlyn M. Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 1009-11. PMID 16571776 DOI: 10.1096/fj.05-4880fje  1
2006 Herlyn M. Molecular targets in melanoma: Strategies and challenges for diagnosis and therapy International Journal of Cancer. 118: 523-526. PMID 16258898 DOI: 10.1002/ijc.21605  1
2006 Fang D, Herlyn M. The dynamic roles of cell-surface receptors in melanoma development From Melanocytes to Melanoma: the Progression to Malignancy. 169-181. DOI: 10.1007/978-1-59259-994-3_9  1
2005 Smalley KSM, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics Annals of the New York Academy of Sciences. 1059: 16-25. PMID 16382039 DOI: 10.1196/annals.1339.005  1
2005 Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma The Journal of Investigative Dermatology. Symposium Proceedings / the Society For Investigative Dermatology, Inc. [and] European Society For Dermatological Research.. 10: 153-163. PMID 16358819  1
2005 Smalley KSM, Lioni M, Herlyn M. Targeting the stromal fibroblasts: A novel approach to melanoma therapy Expert Review of Anticancer Therapy. 5: 1069-1078. PMID 16336098 DOI: 10.1586/14737140.5.6.1069  1
2005 Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco AJ, Herlyn M, Liu ZJ. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. The Journal of Clinical Investigation. 115: 3166-76. PMID 16239965 DOI: 10.1172/JCI25001  1
2005 Smalley KSM, Brafford PA, Herlyn M. Selective evolutionary pressure from the tissue microenvironment drives tumor progression Seminars in Cancer Biology. 15: 451-459. PMID 16043361 DOI: 10.1016/j.semcancer.2005.06.002  1
2005 Li G, Herlyn M. Information sharing and collateral damage Trends in Molecular Medicine. 11: 350-352. PMID 16002338 DOI: 10.1016/j.molmed.2005.06.009  1
2005 Herlyn M. Cancer and Metastasis Reviews: Introduction Cancer and Metastasis Reviews. 24: 193-194. PMID 15986131 DOI: 10.1007/s10555-005-1571-2  1
2005 Hsu MY, Li L, Herlyn M. Cultivation of normal human epidermal melanocytes in the absence of phorbol esters Methods in Molecular Medicine. 107: 13-28. PMID 15492362  1
2005 Brafford P, Herlyn M. Gene expression profiling of melanoma cells - Searching the haystack Journal of Translational Medicine. 3. DOI: 10.1186/1479-5876-3-2  1
2005 Herlyn M. Guest editor Cancer and Metastasis Reviews. 24. DOI: 10.1007/s10555-005-1584-x  1
2004 Smalley KSM, Herlyn M. Loitering with intent: New evidence for the role of BRAF mutations in the proliferation of melanocytic lesions Journal of Investigative Dermatology. 123. PMID 15373800 DOI: 10.1111/j.0022-202X.2004.23430.x  1
2004 Haass NK, Smalley KSM, Herlyn M. The role of altered cell-cell communication in melanoma progression Journal of Molecular Histology. 35: 309-318. PMID 15339050 DOI: 10.1023/B:HIJO.0000032362.35354.bb  1
2004 Li G, Fukunaga M, Herlyn M. Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding β-catenin signaling Experimental Cell Research. 297: 142-151. PMID 15194432 DOI: 10.1016/j.yexcr.2004.03.012  1
2004 Perlis C, Herlyn M. Recent Advances in Melanoma Biology Oncologist. 9: 182-187. PMID 15047922 DOI: 10.1634/theoncologist.9-2-182  1
2003 Ruiter DJ, Herlyn M. [Melanoma-stroma interactions and melanoma progression]. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg. 1: 773-6. PMID 16281812 DOI: 10.1046/j.1439-0353.2003.03026.x  1
2003 Herlyn M, Guerry IV D. First International Melanoma Research Congress Cancer Biology and Therapy. 2: 721-724. PMID 14688485 DOI: 10.4161/cbt.2.6.513  1
2003 Smalley KSM, Herlyn M. The Great Escape: Another Way for Melanoma to Leave Physiological Control? Journal of Investigative Dermatology. 121. PMID 14632176 DOI: 10.1046/j.1523-1747.2003.12506.x  1
2003 Bogenrieder T, Herlyn M. Axis of evil: Molecular mechanisms of cancer metastasis Oncogene. 22: 6524-6536. PMID 14528277  1
2003 Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 4: 95-8. PMID 12957284 DOI: 10.1016/S1535-6108(03)00189-2  1
2003 Liu ZJ, Herlyn M. Slit-Robo: Neuronal guides signal in tumor angiogenesis Cancer Cell. 4: 1-2. PMID 12892705 DOI: 10.1016/S1535-6108(03)00166-1  1
2003 Velazquez OC, Herlyn M. The vascular phenotype of melanoma metastasis Clinical and Experimental Metastasis. 20: 229-235. PMID 12741681 DOI: 10.1023/A:1022987201264  1
2003 Satyamoorthy K, Herlyn M. p16INK4A and familial melanoma Methods in Molecular Biology (Clifton, N.J.). 222: 185-195. PMID 12710687  1
2002 Hsu MY, Meier F, Herlyn M. Melanoma development and progression: A conspiracy between tumor and host Differentiation. 70: 522-536. PMID 12492494 DOI: 10.1046/j.1432-0436.2002.700906.x  1
2002 Bogenrieder T, Herlyn M. Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma Critical Reviews in Oncology/Hematology. 44: 1-15. PMID 12398996 DOI: 10.1016/S1040-8428(01)00196-2  1
2002 Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma Cancer Gene Therapy. 9: 807-812. PMID 12224020 DOI: 10.1038/sj.cgt.7700492  1
2002 Satyamoorthy K, Herlyn M. Cellular and molecular biology of human melanoma Cancer Biology and Therapy. 1: 14-17. PMID 12170758 DOI: 10.4161/cbt.1.1.32  1
2002 Li G, Satyamoorthy K, Herlyn M. Dynamics of cell interactions and communications during melanoma development Critical Reviews in Oral Biology and Medicine. 13: 62-70. PMID 12097238  1
2002 Herlyn M. Emerging concepts and technologies in melanoma research Melanoma Research. 12: 3-8. PMID 11828252 DOI: 10.1097/00008390-200202000-00002  1
2001 Sauter ER, Tichansky D, Furth EE, Herlyn M. Tumor-associated antigen expression and growth requirements predict tumorigenesis in squamous cell carcinoma In Vitro Cellular and Developmental Biology - Animal. 37: 530-535. PMID 11669287 DOI: 10.1290/1071-2690(2001)037<0530:TAAEAG>2.0.CO;2  1
2001 Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells Journal of Immunology. 166: 6483-6490. PMID 11359798  1
2001 Berking C, Herlyn M. Human skin reconstruct models: A new application for studies of melanocyte and melanoma biology Histology and Histopathology. 16: 669-674. PMID 11332722  1
2001 Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells Cancer Research. 61: 3819-3825. PMID 11325858  1
2001 Satyamoorthy K, Bogenrieder T, Herlyn M. No longer a molecular black box - New clues to apoptosis and drug resistance in melanoma Trends in Molecular Medicine. 7: 191-194. PMID 11325619 DOI: 10.1016/S1471-4914(01)02013-5  1
2001 Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma Current Opinion in Oncology. 13: 117-123. PMID 11224709 DOI: 10.1097/00001622-200103000-00006  1
2000 Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society. 8: 480-93. PMID 11208175 DOI: 10.1046/j.1524-475X.2000.00480.x  1
2000 Satyamoorthy K, Oka M, Herlyn M. An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin Pigment Cell Research. 13: 87-93. PMID 11041363  1
2000 Herlyn M, Barking C, Li G, Satyamoorthy K. Lessons from melanocyte development for understanding the biological events in naevus melanoma formation Melanoma Research. 10: 303-312. PMID 10985664  1
2000 Li G, Herlyn M. Dynamics of intercellular communication during melanoma development Molecular Medicine Today. 6: 163-169. PMID 10740255 DOI: 10.1016/S1357-4310(00)01692-0  1
1999 Herlyn M. Endothelial cells as targets for tumor therapy: Editorial Journal of Immunotherapy. 22: 185. PMID 10335478 DOI: 10.1097/00002371-199905000-00001  1
1998 Sauter ER, Herlyn M. Molecular biology of human melanoma development and progression Molecular Carcinogenesis. 23: 132-143. PMID 9833774 DOI: 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1  1
1998 Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin- embedded tissue Modern Pathology. 11: 1098-1106. PMID 9831208  1
1997 Shih IM, Hsu MY, Palazzo JP, Herlyn M. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma American Journal of Pathology. 151: 745-751. PMID 9284823  1
1997 Wechsler-Reya R, Elliott K, Herlyn M, Prendergast GC. The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Cancer Research. 57: 3258-63. PMID 9242458  1
1996 Juhász I, Simon M, Herlyn M, Hunyadi J. Repopulation of Langerhans cells during wound healing in an experimental human skin/SCID mouse model Immunology Letters. 52: 125-128. PMID 8905406 DOI: 10.1016/0165-2478(96)02596-5  1
1996 Herlyn M, Satyamoorthy K. Activated ras. Yet another player in melanoma? The American Journal of Pathology. 149: 739-744. PMID 8780377  1
1996 Simon M, Juhász I, Herlyn M, Hunyadi J. Thrombospondin receptor (CD36) expression of human keratinocytes during wound healing in a SCID mouse/human skin repair model Journal of Dermatology. 23: 305-309. PMID 8675818  1
1996 Herlyn M. ME 491 Hybridoma. 15: 167.  1
1996 Herlyn M, Lazzaro B. ME 67-6 Hybridoma. 15: 166.  1
1995 Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis International Journal of Cancer. 60: 129-136. PMID 7814145 DOI: 10.1002/ijc.2910600119  1
1994 Shih IM, Speicher D, Elder DE, Herlyn M, Johnson JP. Isolation and Functional Characterization of the A32 Melanoma-associated Antigen Cancer Research. 54: 2514-2520. PMID 8162602  1
1994 Herlyn M, Shih IM. Interactions of melanocytes and melanoma cells with the microenvironment Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 7: 81-88. PMID 8066024  1
1994 Gratas C, Herlyn M, Becker D. Isolation and analysis of novel human melanocyte-specific cDNA clones Dna and Cell Biology. 13: 515-519. PMID 8024694  1
1994 Soballe PW, Herlyn M. Cellular pathways leading to melanoma differentiation: Therapeutic implications Melanoma Research. 4: 213-223. PMID 7950357  1
1994 Shih LM, Elder DE, Hsu MY, Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes American Journal of Pathology. 145: 837-845. PMID 7943174  1
1994 Nesbit M, Herlyn M. Adhesion receptors in human melanoma progression Invasion and Metastasis. 14: 131-146. PMID 7657508  1
1994 Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma In Vivo. 8: 113-123. PMID 7519892  1
1993 Shih IM, Herlyn M. Role of growth factors and their receptors in the development and progression of melanoma Journal of Investigative Dermatology. 100. PMID 8381840  1
1993 Menrad A, Speicher D, Wacker J, Herlyn M. Biochemical and Functional Characterization of Aminopeptidase N Expressed by Human Melanoma Cells Cancer Research. 53: 1450-1455. PMID 8095183  1
1992 Menrad A, Herlyn M. Tumor progression, biology, and host response in melanoma Current Opinion in Oncology. 4: 351-356. PMID 1591308  1
1992 Graeven U, Herlyn M. In vitro growth patterns of normal human melanocytes and melanocytes from different stages of melanoma progression Journal of Immunotherapy. 12: 199-202. PMID 1445812  1
1992 Becker D, Lee PL, Rodeck U, Herlyn M. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation Oncogene. 7: 2303-2313. PMID 1437152  1
1992 Elder DE, Herlyn M. Antigens associated with tumor progression in melanocytic neoplasia Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 136-143. PMID 1409415  1
1992 Graeven U, Rodeck U, Weinmann R, Herlyn M. Stable transfection of human malignant melanoma cells with basic fibroblast growth factor antisense cDNA Annals of the New York Academy of Sciences. 660: 293-294. PMID 1340139 DOI: 10.1111/j.1749-6632.1992.tb21090.x  1
1991 Rodeck U, Becker D, Herlyn M. Basic fibroblast growth factor in human melanoma Cancer Cells. 3: 308-311. PMID 1931440  1
1991 Herlyn M, Malkowicz SB. Biology of disease. Regulatory pathways in tumor growth and invasion Laboratory Investigation. 65: 262-271. PMID 1890806  1
1991 Rodeck U, Herlyn M. Growth factors in melanoma Cancer and Metastasis Review. 10: 89-101. PMID 1873858 DOI: 10.1007/BF00049407  1
1991 Brocker EB, Magiera H, Herlyn M. Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin Journal of Investigative Dermatology. 96: 662-665. PMID 1850772  1
1991 Herlyn D, Linnenbach A, Koprowski H, Herlyn M. Epitope- and antigen-specific cancer vaccines International Reviews of Immunology. 7: 245-257. PMID 1779173 DOI: 10.3109/08830189109114874  1
1991 Valyi-Nagy IT, Herlyn M. Regulation of growth and phenotype of normal human melanocytes in culture Cancer Treatment and Research. 54: 85-101. PMID 1673861  1
1991 Herlyn D, Adachi K, Koprowski H, Herlyn M. Experimental model of human melanoma metastases Cancer Treatment and Research. 54: 105-118. PMID 1673854  1
1990 Becker D, Beebe SJ, Herlyn M. Differential expression of protein kinase C and cAMP-dependent protein kinase in normal human melanocytes and malignant melanomas Oncogene. 5: 1133-1139. PMID 2392322  1
1990 Mancianti ML, Clark WH, Hayes FA, Herlyn M. Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype American Journal of Pathology. 136: 817-829. PMID 2327470  1
1990 Herlyn M. Human melanoma: Development and progression Cancer and Metastasis Review. 9: 101-112. PMID 2253310 DOI: 10.1007/BF00046337  1
1990 Herlyn M, Menrad A, Koprowski H. Structure, function, and clinical significance of human tumor antigens Journal of the National Cancer Institute. 82: 1883-1889. PMID 2250310 DOI: 10.1093/jnci/82.24.1883  1
1990 Rodeck U, Williams N, Murthy U, Herlyn M. Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-α Journal of Cellular Biochemistry. 44: 69-79. PMID 2250044  1
1990 Dion AS, Williams CJ, Herlyn M, Major P. Human milk fat globule membrane glycoproteins express blood group-related determinants primarily on mucin-like epithelial membrane antigens and gp70. Biochemistry International. 22: 295-302. PMID 1708665  1
1989 Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor Embo Journal. 8: 3685-3691. PMID 2684645  1
1989 Kath R, Herlyn M. Molecular biology of tumor antigens Current Opinion in Immunology. 1: 863-866. PMID 2679733 DOI: 10.1016/0952-7915(89)90061-7  1
1989 Mancianti ML, Herlyn M. Tumor progression in melanoma: the biology of epidermal melanocytes in vitro Carcinogenesis; a Comprehensive Survey. 11: 369-386. PMID 2646021  1
1989 Berd D, Herlyn M, Koprowski H, Mastrangelo MJ. Flow Cytometric Determination of the Frequency and Heterogeneity of Expression of Human Melanoma-associated Antigens Cancer Research. 49: 6840-6844. PMID 2582430  1
1989 Williams NN, Daly JM, Herlyn M. Primary colorectal carcinoma cell lines contain subpopulations with invasive properties Surgical Forum. 40: 400-403.  1
1988 Herlyn M, Koprowski H. Melanoma antigens: Immunological and biological characterization and clinical significance Annual Review of Immunology. 6: 283-308. PMID 3289568  1
1988 Rodeck U, Menssen HD, Herlyn M. Growth factors in the pathogenesis of malignant diseases Deutsche Medizinische Wochenschrift. 113: 904-906. PMID 3286186  1
1988 Rodeck U, Herlyn M. Characteristics of cultured human melanocytes from different stages of tumor progression Cancer Treatment and Research. 43: 3-16. PMID 2908575  1
1988 Rakowicz-Szulczyńska EM, Herlyn M, Koprowski IH. Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro Cancer Research. 48: 7200-7206. PMID 2461254  1
1988 Williams NN, Rodeck U, Daly JM, Herlyn M. Growth regulatory factors for human colorectal carcinoma cells in vitro Surgical Forum. 39: 445-447.  1
1987 Herlyn M, Clark WH, Rodeck U. Biology of disease. Biology of tumor progression in human melanocytes Laboratory Investigation. 56: 461-474. PMID 3553733  1
1987 Menssen HD, Herlyn M, Rodeck U, Koprowski H. Rapid dissociation of adherent human tumor cells by ultrasound Journal of Immunological Methods. 104: 1-6. PMID 3316390 DOI: 10.1016/0022-1759(87)90480-7  1
1987 Rodeck U, Atkinson B, Herlyn M, Varello M, Herlyn D, Molthoff C, Steplewski Z, Koprowski H. Tumor Growth Modulation by a Monoclonal Antibody to The Epidermal Growth Factor Receptor: Immunologically Mediated and Effector Cell-Independent Effects Cancer Research. 47: 3692-3696. PMID 3297307  1
1987 Rodeck U, Herlyn M, Koprowski H. Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors Journal of Cellular Biochemistry. 35: 315-320. PMID 2831241  1
1987 Ordonez NG, Freedman RS, Herlyn M. Lewis and related tumor-associated determinants on ovarian carcinoma Gynecologic Oncology. 26: 1-10. PMID 2431961 DOI: 10.1016/0090-8258(87)90065-5  1
1987 Herlyn M, Rodeck U, Koprowski H. Shedding Of Human Tumor-Associated Antigens in Vitro and in Vivo Advances in Cancer Research. 49: 189-221. DOI: 10.1016/S0065-230X(08)60798-8  1
1986 Balaban GB, Herlyn M, Clark WH, Nowell PC. Karyotypic evolution in human malignant melanoma Cancer Genetics and Cytogenetics. 19: 113-122. PMID 3940171 DOI: 10.1016/0165-4608(86)90378-X  1
1986 Herlyn M, Steplewski Z, Herlyn D, Koprowski H. CO 17-1A and related monoclonal antibodies: Their production and characterization Hybridoma. 5. PMID 3744383  1
1986 Koprowska I, Zipfel S, Ross AH, Herlyn M. Development of monoclonal antibodies that recognize antigens associated with human cervical carcinoma Acta Cytologica. 30: 207-213. PMID 3521172  1
1986 Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H. Chromatin binding of epidermal growth factor, nerve growth factor and platelet-derived growth factor in cells bearing the appropriate surface receptor Proceedings of the National Academy of Sciences of the United States of America. 83: 3728-3732. PMID 3012531  1
1985 Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells Cellular Immunology. 92: 105-114. PMID 4075410 DOI: 10.1016/0008-8749(85)90068-1  1
1985 Herlyn M, Guerry D, Koprowski H. Recombinant γ-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells Journal of Immunology. 134: 4226-4236. PMID 2985706  1
1985 Sears HF, Herlyn M, Engstrom PF. Circulating tumor markers and assessment of response to intrahepatic chemotherapy on colon carcinoma American Journal of Clinical Oncology: Cancer Clinical Trials. 8: 108-117. PMID 2939709  1
1985 Koprowska I, Zipfel SA, Himes TR, Herlyn M. Common Antigenic Sites on Exfoliated Cells Derived from Cervical Carcinoma and in Tumor Cells of Nonuterine Origin as Demonstrated by Monoclonal Antibodies in Immunoperoxidase Assay Cancer Research. 45: 5964-5968. PMID 2414003  1
1985 Herlyn M, Guerry D, Balaban G. Human melanocytic cells obtained from different stages of tumor progression retain their phenotypic characteristics in vitro Proceedings of the American Association For Cancer Research 1
1985 Balaban G, Herlyn M, Guerry D. Chromosomal changes parallel clinical stages of disease in melanocytic tumors Proceedings of the American Association For Cancer Research 1
1985 Guerry D, Alexander MA, Elder DE, Herlyn M. Interferon-gamma (IFN-γ) regulates T cell response to melanoma Proceedings of the American Association For Cancer Research 1
1984 Herlyn M, Sears HF, Verrill H, Koprowski H. Increased sensitivity in detecting tumor-associated antigens in sera of patients with colorectal carcinoma Journal of Immunological Methods. 75: 15-21. PMID 6512262 DOI: 10.1016/0022-1759(84)90220-5  1
1984 Donoso LA, Folberg R, Angiolillo P, Herlyn M. A 19-9 monoclonal antibody study of adenocarcinoma metastatic to the choroid American Journal of Ophthalmology. 98: 815-816. PMID 6507563  1
1984 Herlyn D, Herlyn M, Ross AH, Ernst C, Atkinson B, Koprowski H. Efficient selection of human tumor growth-inhibiting monoclonal antibodies Journal of Immunological Methods. 73: 157-167. PMID 6491298 DOI: 10.1016/0022-1759(84)90041-3  1
1983 Herlyn M. Interview with Dr. M. Herlyn, Philadelphia. The new magic formula: monoclonal antibodies Munchener Medizinische Wochenschrift. 125: 16-18, 21. PMID 6413843  1
1983 Steplewski Z, Herlyn M, Blaszczyk M, Koprowski H. A simple procedure for determining Lewis phenotypes in human saliva Journal of Immunological Methods. 62: 73-78. PMID 6348171 DOI: 10.1016/0022-1759(83)90112-6  1
1982 Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma Journal of Clinical Immunology. 2: 135-140. PMID 7068815 DOI: 10.1007/BF00916897  1
1982 Sears HF, Herlyn D, Herlyn M, Steplewski Z, Grotzinger P, Koprowski H. Ex vivo perfusion of human colon with monoclonal anticolorectal cancer antibodies Cancer. 49: 1231-1235. PMID 7059945  1
1982 Herlyn M, Atkinson BF, Steplewski Z, Ernst CS, Sears HF, Koprowski H. Gastrointestinal Cancer-associated Antigen in Immunoperoxidase Assay Cancer Research. 42: 4820-4823. PMID 6751528  1
1981 Steplewski Z, Chang TH, Herlyn M, Koprowski H. Release of monoclonal antibody-defined antigens by human colorectal carcinoma and melanoma cells Cancer Research. 41: 2723-2727. PMID 7248940  1
1981 Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma Science. 212: 53-55. PMID 6163212  1
1980 Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of Growth of Colorectal Carcinoma in Nude Mice by Monoclonal Antibody Cancer Research. 40: 717-721. PMID 7471090  1
1979 Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma European Journal of Immunology. 9: 657-659. PMID 499332  1
1979 Steplewski Z, Herlyn M, Herlyn D, Clark WH, Koprowski H. Reactivity of monoclonal anti-melanoma antibodies with melanoma cells freshly isolated from primary and metastatic melanoma European Journal of Immunology. 9: 94-96. PMID 374094 DOI: 10.1002/eji.1830090120  1
1979 Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies Proceedings of the National Academy of Sciences of the United States of America. 76: 1438-1442. PMID 286328  1
1979 Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies Somatic Cell Genetics. 5: 957-971. PMID 94699 DOI: 10.1007/BF01542654  1
1978 Koprowski H, Steplewski Z, Herlyn D, Herlyn M. Study of antibodies against human melanoma produced by somatic cell hybrids Proceedings of the National Academy of Sciences of the United States of America. 75: 3405-3409. PMID 80012  1
Show low-probability matches.